Welcome to our dedicated page for Xilio Therapeutics news (Ticker: XLO), a resource for investors and traders seeking the latest updates and insights on Xilio Therapeutics stock.
Xilio Therapeutics, Inc. (Nasdaq: XLO) is a clinical-stage biotechnology company developing tumor-activated, or masked, immuno-oncology therapies for people living with cancer. The XLO news feed on Stock Titan aggregates company-issued press releases and related coverage so readers can follow how Xilio’s pipeline, collaborations and financial position evolve over time.
News about Xilio frequently centers on clinical and preclinical data from its key programs. These include vilastobart, an investigational tumor-activated, Fc-enhanced anti-CTLA-4 antibody being studied in combination with atezolizumab in advanced solid tumors and microsatellite stable metastatic colorectal cancer, and efarindodekin alfa (XTX301), a tumor-activated IL-12 in a Phase 1/2 trial for advanced solid tumors. The company also reports on progress for XTX501, a bispecific PD-1 / masked IL-2 molecule in IND-enabling studies, and multiple masked T cell engager programs targeting tumor-associated antigens such as PSMA, CLDN18.2 and STEAP1.
Investors can use this page to track Xilio’s announcements about clinical trial milestones, data presentations at scientific meetings like the Society for Immunotherapy of Cancer (SITC) and the American Society of Clinical Oncology (ASCO), and updates on collaborations with partners including Gilead, Roche and AbbVie. The feed also captures corporate developments such as financings, warrant exercises, cash runway guidance, stock option plans and board or leadership changes disclosed in press releases and related SEC filings.
By reviewing the XLO news stream, readers gain a consolidated view of how Xilio’s masked immunotherapy platform is progressing through research and development, how external partners are engaging with its programs, and how the company is addressing Nasdaq listing requirements and capital needs as it advances its oncology pipeline.
AbbVie (ABBV) and Xilio Therapeutics (XLO) have announced a collaboration and option-to-license agreement to develop novel tumor-activated immunotherapies. The partnership leverages Xilio's proprietary technology platform for developing tumor-activated biologics, including masked T-cell engagers.
The collaboration aims to combine AbbVie's oncology expertise with Xilio's technology to create next-generation cancer treatments focused on tumor-selective activation while minimizing systemic adverse events. Under the agreement terms, Xilio will receive $52.0 million in total upfront payments, including a $10.0M equity investment, and will be eligible for up to $2.1 billion in contingent payments plus tiered royalties.
Xilio Therapeutics (Nasdaq: XLO), a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, has granted stock options to four new employees. The grants, effective February 1, 2025, consist of non-qualified stock options to purchase 83,400 shares of common stock at an exercise price of $0.705 per share, matching the closing price on January 31, 2025.
The options have a ten-year term with a vesting schedule of 25% after the first year of employment, followed by the remaining 75% vesting in 36 monthly installments. These grants were made under Xilio's 2022 Inducement Stock Incentive Plan as employment inducements in accordance with Nasdaq Listing Rule 5635(c)(4).
Xilio Therapeutics (Nasdaq: XLO) announced initial Phase 2 data for vilastobart (XTX101) combined with atezolizumab in treating metastatic microsatellite stable colorectal cancer (MSS CRC). The trial showed a 27% preliminary response rate in patients without liver metastases, with three partial responses including two confirmed ones.
Key findings include decreased levels of carcinoembryonic antigen (CEA) and circulating tumor DNA (ctDNA), along with improved clinical symptoms. Among 40 treated patients, the combination demonstrated a favorable safety profile with low immune-related adverse events and only 5% reporting colitis. Of the 18 patients evaluable for response, 11 without liver metastases showed promising results, with responses ongoing at data cutoff.
The company plans to report updated Phase 2 data in mid-2025 and is seeking partnership opportunities to expand development beyond the initial MSS CRC trial.
Xilio Therapeutics (Nasdaq: XLO), a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, has granted a non-qualified stock option to a new employee. The option, effective January 1, 2025, allows for the purchase of 60,000 shares of common stock at an exercise price of $0.955 per share, matching the company's closing price on December 31, 2024.
The stock option has a ten-year term with a vesting schedule of 25% after the first year of employment, followed by the remaining 75% vesting in 36 monthly installments. This grant was made under Xilio's 2022 Inducement Stock Incentive Plan and complies with Nasdaq Listing Rule 5635(c)(4).
Xilio Therapeutics (Nasdaq: XLO), a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, has granted a non-qualified stock option to its new Chief Legal Officer, Caroline Hensley. The option, effective January 1, 2025, allows for the purchase of 375,000 shares of common stock at an exercise price of $0.955 per share, matching the company's closing price on December 31, 2024.
The stock option has a ten-year term with a vesting schedule where 25% of shares vest after the first year of employment, followed by the remaining 75% vesting in 36 monthly installments. This grant was made under Xilio's 2022 Inducement Stock Incentive Plan and complies with Nasdaq Listing Rule 5635(c)(4).
Xilio Therapeutics (XLO) announced plans to present initial Phase 2 data for vilastobart (XTX101), their tumor-activated anti-CTLA-4 therapy, in combination with atezolizumab for metastatic microsatellite stable colorectal cancer at ASCO GI in January 2025. The company also reported preliminary Phase 1 data for XTX301, their tumor-activated IL-12 therapy, showing improved tolerability with no dose-limiting toxicities across 34 patients treated at doses from 5 µg/kg to 60 µg/kg.
The company completed an additional $8.2 million private placement with Gilead, reaching the maximum $25 million investment under their March 2024 agreement. With these proceeds, Xilio expects to fund operations into Q3 2025.
Xilio Therapeutics (Nasdaq: XLO) has appointed Caroline Hensley as chief legal officer. Hensley joins from Seres Therapeutics, where she served as senior vice president, assistant general counsel and chief compliance officer, overseeing corporate legal and compliance matters. Her experience includes managing capital markets transactions, clinical development activities, commercial launches, and FDA regulatory compliance. Previously, she worked as a corporate associate at Latham & Watkins, representing biotechnology companies in various transactions. Hensley holds a B.A. in economics from the University of Texas at Austin and a J.D. from Boston University School of Law.
Xilio Therapeutics (Nasdaq: XLO), a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, has granted stock options to a new employee. The grant, effective December 1, 2024, consists of non-qualified stock options to purchase 8,400 shares of common stock at an exercise price of $1.09 per share, matching the closing price on November 29, 2024.
The options have a ten-year term with a vesting schedule of 25% after the first year and the remaining 75% vesting monthly over three years. These grants were made under Xilio's 2022 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Xilio Therapeutics announced initial clinical data from Phase 1C trial evaluating vilastobart combined with atezolizumab in advanced solid tumor patients. The combination showed promising anti-tumor activity, including two unconfirmed partial responses in patients with immunologically 'cold' tumors. A notable complete resolution of a metastatic liver lesion was observed in a patient with microsatellite stable colorectal cancer (MSS CRC). The treatment was generally well-tolerated, with no Grade 4 or 5 treatment-related adverse events reported. Initial Phase 2 data for the combination in metastatic MSS CRC patients is expected in Q4 2024.
Xilio Therapeutics (Nasdaq: XLO) reported Q3 2024 financial results and pipeline updates. The company will present initial Phase 1C data for vilastobart combined with atezolizumab at SITC Annual Meeting. Key financial metrics include cash position of $61.3 million, license revenue of $2.3 million, and net loss of $14.0 million. R&D expenses decreased to $10.8 million from $11.1 million year-over-year, while G&A expenses remained stable at $6.3 million. The company expects current cash to fund operations through Q2 2025.